WINTON GROUP Ltd Invests $5.73 Million in Ralliant Corporation $RAL

WINTON GROUP Ltd acquired a new position in shares of Ralliant Corporation (NYSE:RAL) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 112,521 shares of the company’s stock, valued at approximately $5,728,000. WINTON GROUP Ltd owned 0.10% of Ralliant as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Danske Bank A S acquired a new stake in Ralliant in the fourth quarter worth $25,000. Allworth Financial LP grew its holdings in Ralliant by 134.4% in the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after purchasing an additional 293 shares during the period. V Square Quantitative Management LLC acquired a new stake in Ralliant in the fourth quarter worth $26,000. Palisade Asset Management LLC acquired a new stake in Ralliant in the third quarter worth $26,000. Finally, Rothschild Investment LLC grew its holdings in Ralliant by 98.1% in the fourth quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock worth $31,000 after purchasing an additional 303 shares during the period.

Ralliant Stock Down 3.6%

Shares of NYSE RAL opened at $60.18 on Friday. The stock has a market capitalization of $6.74 billion and a P/E ratio of -5.50. The company has a 50-day moving average price of $50.75 and a 200-day moving average price of $49.20. Ralliant Corporation has a 1 year low of $37.27 and a 1 year high of $63.31. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 1.05.

Ralliant (NYSE:RAL) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. The firm had revenue of $534.60 million during the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The company’s quarterly revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, equities research analysts forecast that Ralliant Corporation will post 2.64 EPS for the current fiscal year.

Ralliant Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 23rd. Investors of record on Monday, June 8th will be paid a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, June 8th. This represents a $0.20 annualized dividend and a yield of 0.3%. Ralliant’s payout ratio is currently -1.83%.

Analyst Ratings Changes

A number of research firms have commented on RAL. Vertical Research cut shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price target for the company. in a report on Wednesday, May 27th. Morgan Stanley raised their price target on shares of Ralliant from $45.00 to $68.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. TD Cowen raised their price target on shares of Ralliant from $55.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, May 20th. Oppenheimer raised their price target on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, May 13th. Finally, Royal Bank Of Canada raised their price target on shares of Ralliant from $47.00 to $64.00 and gave the stock a “sector perform” rating in a report on Wednesday, May 13th. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Ralliant has an average rating of “Hold” and an average price target of $64.50.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.